The global antimicrobial resistance market was valued at USD 9.64 Billion in 2025. The market is anticipated to grow at a CAGR of 5.27% during the forecast period of 2026-2035, with the values likely to reach USD 16.11 Billion by 2035. The market is fueled by increasing awareness of antimicrobial stewardship, rising incidence of drug-resistant infections, and growing R&D investments in novel antibiotics and diagnostic tools. Expansion of public-private collaborations and regulatory support for innovative therapies are expected to enhance market growth, while the introduction of advanced molecular diagnostics will further strengthen market potential during the forecast period.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
5.27%
Value in USD Billion
2026-2035
*this image is indicative*
Antibiotic resistance happens when bacteria adapt to withstand antibiotics, leading to infections that are hard to treat. Bacteria create defense mechanisms by undergoing genetic mutations, which allow them to resist, survive, and propagate. The increase in antibiotic-resistant infections is driven by the excessive or incorrect use of antibiotics. Taking antibiotics only when needed is essential because they are ineffective against viral infections. As a result, effective treatments are required to tackle this increasing problem.
Increasing Prevalence of Antibiotic-Resistant Infections to Affect the Market Landscape Significantly
The rising cases of antibiotic-resistant bacterial infections necessitate the creation of fresh treatment choices. Annually, more than 2.8 million infections in the United States are resistant to antimicrobial treatment. Considering traditional antibiotics becoming less effective, new treatments are necessary to combat resistant strains. This motivates the search for novel medications and methods.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Indication
Market Breakup by Drug Class
Market Breakup by Pathogen Type
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on Pathogen Type to Witness Substantial Growth
Based on pathogen type, the market is segmented into escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, staphylococcus aureus, staphylococcus pneumoniae, and others. The Klebsiella pneumoniae segment is expected to lead the market as it is resistant to various antibiotics. The presence of extended-spectrum beta-lactamases and carbapenemases in the gram-negative bacterium hinders treatment. The capability for transferring genes helps in disseminating resistance.
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. High levels of antibiotic resistance and a strong healthcare system make North America lead the market. The Asia Pacific region is experiencing rapid growth and is also seeing a surge in antibiotic resistance due to the high prevalence of infectious diseases and inappropriate antibiotic usage.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Melinta Therapeutics is a biopharmaceutical company established in 2000 and is actively involved in the fabrication of new broad-spectrum antibiotics to combat antibiotic-resistant infections found in hospital settings. Their partnership with Venatorx Pharmaceuticals is focused on combating global antimicrobial resistance by developing the novel antibiotic, cefepime-taniborbactam.
Nabriva Therapeutics creates new antibiotics for curing infections, having a significant role in the global antimicrobial resistance market. The company renewed its exclusive deal with Merck & Co. to distribute SIVEXTRO, an antibiotic for acute bacterial skin and skin structure infections from bacteria in the United States.
Pfizer Inc., a global pharmaceutical company headquartered in Manhattan, shares an encouraging committee for medicinal products for human use view on EMBLAVEO®, an antibiotic mix to combat drug-resistant infections.
Basilea Pharmaceutica, headquartered in Switzerland, is combating antimicrobial resistance by utilizing the FDA-approved antibiotic ceftobiprole to treat bacterial infections, such as multidrug-resistant strains like Staphylococcus aureus, in support of global healthcare initiatives.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Cumberland Pharmaceuticals, Merck & Co. Inc., Acurx Pharmaceuticals, Inc., Innoviva, Inc., Alkem Laboratories Ltd., Paratek Pharmaceuticals Inc.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Drug Class |
|
| Breakup by Pathogen Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share